Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3839840 · 1 trial · 1 indication
A summary of AEs, TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the reported adverse events module
| Arm | Type | Description |
|---|---|---|
| LY3839840 (Part A) | EXPERIMENTAL | Single ascending dose of LY3839840 administered orally. |
| LY3839840 (Part B) Cohort 1-3 | EXPERIMENTAL | Multiple ascending dose of LY3839840 administered orally. |
| LY3839840 (Part B) Cohort 4 | EXPERIMENTAL | Multiple ascending dose of LY3839840 administered orally. |
| LY3839840 (Part B) Optional Cohort 5 | EXPERIMENTAL | Multiple ascending dose of LY3839840 administered orally pending data from Cohort 4 |
| LY3839840 (Part C) | EXPERIMENTAL | Single and multiple dose of LY3839840 administered orally in Chinese participants. |
| LY3839840 (Part D) | EXPERIMENTAL | Multiple ascending dose of LY3839840 administered orally in Japanese participants. |
| Placebo (Parts A-D) | PLACEBO_COMPARATOR | Placebo administered orally. |
| Midazolam (Part E) | EXPERIMENTAL | Midazolam substrate alone or with LY3839840 administered orally |
| Name | Type | Description |
|---|---|---|
| LY3839840 | DRUG | Administered orally. |
| Placebo | DRUG | Administered orally. |
| Midazolam | DRUG | Administered orally |
Inclusion Criteria: Healthy men and women. Women may only be included if they are of nonchildbearing potential For Part C: • Part C of the study includes Chinese participants only. To qualify, the participants must be considered as native Chinese, defined as all the participant's biological grand...
LY3839840 is an investigational small molecule being developed by Eli Lilly and Company. It has been studied in a first-in-human Phase 1 clinical trial in healthy adult participants. The specific disease or condition it is intended to treat has not been disclosed.
LY3839840 is being developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly conducted the first-in-human study of the compound in the United States.
LY3839840 is in Phase 1 development. Its single first-in-human trial, NCT06153355, has been completed. The study enrolled 140 healthy adult participants and was randomized, double-blind, and placebo-controlled.
LY3839840 has been evaluated in one clinical trial, NCT06153355, titled A First-In-Human Study of LY3839840 in Healthy Participants. The Phase 1 trial enrolled 140 healthy volunteers in the United States, included both sexes, and has been completed.
LY3839840 is not approved. It is an investigational small molecule that has completed a single Phase 1 first-in-human trial in healthy volunteers, so it remains in clinical development.